Masterton, RG, Bassetti, M, Chastre, J et al. (6 more authors) (2019) Valuing antibiotics: The role of the hospital clinician. International Journal of Antimicrobial Agents, 54 (1). pp. 16-22. ISSN 0924-8579
Abstract
The global public health threat of antibiotic-resistant infections as well as the lack of new treatments in clinical development is a critical issue. Reasons for this include diminished commercial incentives for pharmaceutical companies to develop new antibiotics, which part-reflects a shift in antibiotic marketing paradigm from broad deployment to targeted therapy in relatively small patient populations. Such changes are encouraged by antimicrobial stewardship (AMS). Other factors include a lack of recognition in the traditional assessment of new antibiotics by regulators, health technology assessors and payers of the broad range of benefits of new agents, particularly their value to health care, economies and society. Recognising the seriousness of the situation, there have been recent changes and proposals by regulators for modification of the assessment process to accommodate a broader range of acceptable data supporting new drug applications. There is also increasing recognition by some payers of the societal benefit of new antibiotics and the need for financial incentives for those developing high-priority antibiotics. However, progress is slow, with recent publications focusing on industry and strategic perspectives rather than clinical implications. In this opinion piece, we therefore focus on clinicians and the practical steps they can take to drive and contribute to increasing awareness and understanding of the value of antibiotics. This includes identifying and gathering appropriate alternative data sources, educating on AMS and prescribing habits, and contributing to international antibiotic susceptibility surveillance models.
Metadata
Item Type: | Article |
---|---|
Authors/Creators: |
|
Copyright, Publisher and Additional Information: | © 2019 Elsevier B.V. and International Society of Chemotherapy. All rights reserved. This is an author produced version of an article published in the International Journal of Antimicrobial Agents. Uploaded in accordance with the publisher's self-archiving policy. |
Keywords: | Antibiotic resistance; Antibiotic value; Antimicrobial stewardship; Development pipeline; Health technology assessment |
Dates: |
|
Institution: | The University of Leeds |
Academic Units: | The University of Leeds > Faculty of Medicine and Health (Leeds) > Institute of Molecular Medicine (LIMM) (Leeds) > Section of Molecular Gastroenterology (Leeds) |
Depositing User: | Symplectic Publications |
Date Deposited: | 12 Jun 2019 15:22 |
Last Modified: | 11 May 2020 00:40 |
Status: | Published |
Publisher: | Elsevier |
Identification Number: | 10.1016/j.ijantimicag.2019.05.012 |
Open Archives Initiative ID (OAI ID): | oai:eprints.whiterose.ac.uk:146988 |